What is B. Riley’s Estimate for Altimmune FY2024 Earnings?

Altimmune, Inc. (NASDAQ:ALT) – Research analysts at B. Riley decreased their FY2024 earnings estimates for shares of Altimmune in a research report issued on Wednesday, November 13th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings of ($1.40) per share for the year, down from their previous forecast of $1.96. B. Riley has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($0.54) per share. B. Riley also issued estimates for Altimmune’s Q4 2024 earnings at ($0.39) EPS, Q2 2025 earnings at $2.33 EPS, Q3 2025 earnings at ($0.54) EPS and Q4 2025 earnings at ($0.64) EPS.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million during the quarter. During the same period in the prior year, the company posted ($0.39) earnings per share.

A number of other equities analysts also recently weighed in on the stock. Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. UBS Group initiated coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Altimmune Stock Down 10.0 %

ALT stock opened at $7.61 on Friday. The company has a 50 day moving average of $7.02 and a two-hundred day moving average of $6.91. The company has a market cap of $541.22 million, a price-to-earnings ratio of -4.91 and a beta of 0.09. Altimmune has a 12-month low of $2.34 and a 12-month high of $14.84.

Hedge Funds Weigh In On Altimmune

Several large investors have recently made changes to their positions in ALT. Larson Financial Group LLC bought a new position in Altimmune during the third quarter worth $31,000. CANADA LIFE ASSURANCE Co bought a new position in shares of Altimmune during the 1st quarter worth about $44,000. TFO Wealth Partners LLC acquired a new position in shares of Altimmune during the first quarter valued at about $51,000. Horizon Wealth Management LLC bought a new stake in shares of Altimmune in the second quarter valued at about $66,000. Finally, PFG Investments LLC acquired a new stake in Altimmune during the second quarter worth about $67,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Insider Transactions at Altimmune

In other news, Director David Drutz sold 16,011 shares of Altimmune stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $6.90, for a total value of $110,475.90. Following the transaction, the director now owns 41,958 shares of the company’s stock, valued at $289,510.20. This trade represents a 27.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.10% of the stock is currently owned by corporate insiders.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.